A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources
Poster Jun 29, 2016
Mira Genser-Nir, Sharon Daniliuc, Marina Tevrovsky, Roni Hazan Brill, Yuliya-Yael Miropolski, David Fiorentini.
Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells that can be isolated from various tissues as well as generated in vitro from hESCs and iPS cells. hMSCs have at least trilineage differentiation potential in vitro (into fat, bone, and cartilage cells), and it is part of the Minimal Experimental Criteria for MSC proposed by the International Society for Cellular Therapy (ISCT). In addition, differentiation of hMSCs into specific lineage provides the basis for the use of human MSC in cell therapy applications. Either undifferentiated
hMSCs can be used for in vivo implantation into damaged tissue sites. The differentiation potential may differ in relation to the culture condition and the source of hMSCs, and it is still unknown which source should be used for each specific disease.
The quality of the culture medium and differentiation media is particularly crucial with regard to therapeutic applications since multipotent hMSCs and differentiated cell properties can be significantly affected by medium components, culture condition, and the manual used for culturing and differentiation.
To date, most of the common differentiation media are composed of FBS and xenogenic compounds, which is a major drawback for both research and clinical applications. Improving the culture conditions and differentiation potential is required for differentiated hMSCs to become the cells of choice for use in modern regenerative medicine and drug screening.
The present study addressed the development of novel serum-free, xenofree media and supplements that efficiently differentiate hMSCs from various sources into adipocytes, osteoblasts, and chondrocytes. Molecular characterization and functional assays were used to evaluate the quality and purity of the differentiated cells.
This novel SF, XF system enables achieving defined conditions for rapid
generation of differentiated hMSCs towards tissue engineering and drug screening applications
We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019